Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Pro Medicus: The Roll-Out Has Just Begun - Aug 22, 2016 

Protagonist Raises $117m, Lists on Nasdaq For Peptide Drugs

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Teva Returns Mesoblast Heart Drug; Equity Facility - Jun 14, 2016

Biotech Daily Policy On Mega-Day-Traders - May 3, 2016

2015 - The Year In Review

Novartis Buys Spinifex For $916m

Genetic Technologies Dr Mervyn Jacobson 12 Months Gaol

Gaol For The Phosphagenics Three: Dr Esra Ogru
Dr Robert Gianello, Dr Woei-Jia Jiang

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


July BDI-40 Up 15%, ASX200 Up 6%
Big Caps Up 6%, NBI Up 14%

Osprey Up 62%, Antisense 60%, Impedimed 41%, Uscom 37%


August 1, 2016
July was good for the S&P ASX200, up 6.3 percent, but it was much better for the Biotech Daily Top 40 Index (BDI-40) which climbed 14.6 percent.
The BDI-40, which does not include the three Big Caps of Cochlear, CSL and Resmed, rose 17.0 percent for the year to July 31, compared to the ASX200 falling 2.4 percent.
The three Big Caps were up an average 6.4 percent for the month to July 31, 2016 to a collective market capitalization of a record $74,372 million, and up 22.8 percent for the 12 months. Resmed was up 10.8 percent to $12,914 million, followed by Cochlear up 9.5 percent to $7,593 million and CSL up 4.95 percent to $53,865 million.
In July, 30 of the BDI-40 companies were up, 20 by more than 10 percent and 12 by more than 20 percent, with just six companies losing ground, the worst by just 8.9 percent.
While Sirtex contributed $350 million to the BDI-40’s collective market capitalization, Impedimed and Nanosonics were both up by more than $145 million.
From low bases, Osprey was the best, recovering a further 61.8 percent to $55 million followed by Antisense up 60 percent to $8 million. Impedimed climbed 41.4 percent, followed by Uscom (37.0%), Opthea (31.1%), Benitec (28.6%), Orthocell (26.3%), Nanosonics (25.2%), Avita (24.5%), Sirtex (23.9%) and IDT (20.4%).
Universal Biosensors led the falls, down 8.9 percent to $51 million, followed by Viralytics (8.5%), Genetic Technologies (6.1%), Medical Developments (2.0%) and Prana (1.9%).
The July Nasdaq Biotech Index rose 14.4 percent, with former Australian companies Heartware down 1.5 percent to $1,338 million, Aviragen (Biota) down 4.1 percent to $70 million and Sunshine Heart rebounding 83.3 percent from a long-term low to $22 million. Israel’s Redhill, developing Giaconda’s assets, climbed 20.2 percent to $220 million.
Outside the BDI-40, Analytic doubled to $22 million and generics manufacturer Mayne Pharma climbed 93.6 percent to $2,987 million, with Cyclopharm, Innate and Resapp at all-time highs of $84 million, $83 million and $228 million, respectively. 
BDI-40 v S&P ASX200 Jun 30, 2006 to Jul 31, 2016 
BDI-40 v S&P ASX200 Jul 31, 2015 to Jul 31, 2016 
Big Caps (Cochlear, CSL, Resmed) Jun 30, 2015 to Jul 31, 2016


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At July 31, 2016



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: